Doctors track new stomach cancer Drug's Real-World side effects
NCT ID NCT06902545
Summary
This study is collecting information on the safety of VYLOY, an already approved drug, for people in South Korea with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. About 377 patients receiving VYLOY as part of their standard care will be observed for about a year. The main goal is to monitor side effects and see how long the cancer remains stable in a real-world clinic setting.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UNRESECTABLE GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA OR CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
KR82001
RECRUITINGSeoul, South Korea
-
KR82002
RECRUITINGSeoul, South Korea
-
KR82003
RECRUITINGSeoul, South Korea
-
KR82004
RECRUITINGSeoul, South Korea
-
KR82005
RECRUITINGSeoul, South Korea
-
KR82006
RECRUITINGYangsan, Gyeongsangnam-do, South Korea
-
KR82007
RECRUITINGSeoul, South Korea
-
KR82008
RECRUITINGSuwon, Gyeonggi-do, South Korea
-
KR82009
RECRUITINGSuwon, Gyeonggi-do, South Korea
-
KR82010
RECRUITINGGoyang-si, Gyeonggi-do, South Korea
-
KR82011
RECRUITINGSeoul, South Korea
-
KR82012
RECRUITINGHwasun Gun, Jeollanam-do, South Korea
-
KR82013
RECRUITINGSeoul, South Korea
Conditions
Explore the condition pages connected to this study.